Abstract
Rationale
The use of intravenous valproate is not approved for clinical practice in psychiatry. Literature data pointed out for a potential usefulness of this route of administration for valproate, but there is no actual consensus.
Objectives
The aim of the present systematic review is to assess the effectiveness of intravenous valproate in agitation as well as general safety.
Methods
A systematic review of studies evaluating the use of intravenous valproate in agitation was conducted. Additionally, safety was evaluated in all randomized trials involving the use of intravenous valproate in all medical conditions (epilepsy, migraine and psychiatric conditions).
Results
For the systematic review on effectiveness in agitation, the search yielded 965 articles overall. After removing duplicates, 9411 articles were screened by title and abstract, and 39 of these were evaluated at a full-text level. Six studies were considered eligible for qualitative synthesis: one RCT and case report (n = 3), followed by cohort studies (n = 2). For the systematic review on safety, twenty-two RCTs were considered eligible for quantitative synthesis.
Conclusion
Intravenous valproate seems efficacious in reducing agitation in psychiatric patients; it generally appears safe compared to other neuroleptics or antiepileptics. However, the evidence is still not strong as it relies mainly on open-label studies or case series.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
13 January 2022
A Correction to this paper has been published: https://doi.org/10.1007/s00213-022-06061-4
References
Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N (2007) Randomized study of intravenous valproate and phenytoin in status epilepticus Seizure-European. J Epilepsy 16:527–532. https://doi.org/10.1016/j.seizure.2007.04.012
Amiri-Nikpour MR, Nazarbaghi S, Eftekhari P, Mohammadi S, Dindarian S, Bagheri M, Mohammadi H (2018) Sodium valproate compared to phenytoin in treatment of status epilepticus. Brain and Behavior 8. https://doi.org/10.1002/brb3.951
Anderson GD, Lin Y, Temkin NR, Fischer JH, Winn HR (2000) Incidence of intravenous site reactions in neurotrauma patients receiving valproate or phenytoin. Ann Pharmacother 34:697–702
Asadollahi S, Heidari K, Hatamabadi H, Vafaee R, Yunesian S, Azadbakht A, Mirmohseni L (2015) Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. Int Clin Psychopharmacol 30:142–150. https://doi.org/10.1097/yic.0000000000000064
Bak M et al (2019) The pharmacological management of agitated and aggressive behaviour: a systematic review and meta-analysis. Eur Psychiatry 57:78–100. https://doi.org/10.1016/j.eurpsy.2019.01.014
Bakhshayesh B, Saadat SMS, Rezania K, Hatamian H, Hossieninezhad M (2013) A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache. Am J Emerg Med 31:540–544. https://doi.org/10.1016/j.ajem.2012.10.014
Battaglia C, Averna R, Labonia M, Riccioni A, Vicari S (2018) Intravenous valproic acid add-on therapy in acute agitation adolescents with suspected substance abuse: a report of six cases. Clin Neuropharmacol 41:38–42. https://doi.org/10.1097/WNF.0000000000000265
Bowden CL (2003) Acute and maintenance treatment with mood stabilizers. Int J Neuropsychopharmacol 6:269–275. https://doi.org/10.1017/S1461145703003535
Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC (1992) Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 12:53S-56S. https://doi.org/10.1097/00004714-199202001-00008
Calabrese JR, Rapport DJ, Kimmel SE, Reece B, Woyshville MJ (1993) Rapid cycling bipolar disorder and its treatment with valproate. Can J Psychiatry 38:S57-61
Chen WB et al (2011) Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. Eur J Neurol 18:1391–1396. https://doi.org/10.1111/j.1468-1331.2011.03420.x
Duggal HS, Jagadheesan K, Gupta S, Basu S, Akhtar S, Nizamie HS (2002) Intravenous valproate: a new perspective in the treatment of manic symptoms. Indian J Psychiatry 44:173–176
Foroughipour M, Ghandehari K, Khazaei M, Ahmadi F, Shariatinezhad K, Ghandehari K (2013) Randomized clinical trial of intravenous valproate (Orifil) and dexamethasone in patients with migraine disorder. Iran J Med Sci 38:150–155
Friedman BW et al (2014) Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology 82:976–983. https://doi.org/10.1212/wnl.0000000000000223
Gagnon DJ et al (2017) Valproate for agitation in critically ill patients: a retrospective study. J Crit Care 37:119–125. https://doi.org/10.1016/j.jcrc.2016.09.006
Ghaleiha A et al (2014) Oral loading of sodium valproate compared to intravenous loading and oral maintenance inacutely manic bipolar patients. Neuropsychobiology 70:29–35. https://doi.org/10.1159/000363344
Gilad R, Izkovitz N, Dabby R, Rapoport A, Sadeh M, Weller B, Lampl Y (2008) Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 118:296–300. https://doi.org/10.1111/j.1600-0404.2008.01097.x
Grunze H, Erfurth A, Amann B, Giupponi G, Kammerer C, Walden J (1999) Intravenous valproate loading in acutely manic and depressed bipolar I patients. J Clin Psychopharmacol 19:303–309. https://doi.org/10.1097/00004714-199908000-00003
Hilty DM, Rodriguez GD, Hales RE (1998) Intravenous valproate for rapid stabilization of agitation in neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 10:365–366. https://doi.org/10.1176/jnp.10.3.365
Hollander E et al (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 35:990–998. https://doi.org/10.1038/npp.2009.202
Hollander E et al (2003) Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 28:1186–1197. https://doi.org/10.1038/sj.npp.1300153
Kapur J et al (2019) Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med 381:2103–2113. https://doi.org/10.1056/NEJMoa1905795
Karimi N, Tavakoli M, Charati JY, Shamsizade M (2017) Single-dose intravenous sodium valproate (depakine) versus dexamethasone for the treatment of acute migraine headache: a double-blind randomized clinical trial. Clin Exp Emerg Med 4:138–145. https://doi.org/10.15441/ceem.16.199
Kongpakwattana K, Sawangjit R, Tawankanjanachot I, Bell JS, Hilmer SN, Chaiyakunapruk N (2018) Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. Br J Clin Pharmacol 84:1445–1456. https://doi.org/10.1111/bcp.13604
Lambert PA, Carraz G, Borselli S, Carbel S (1966) Neuropsychotropic action of a new anti-epileptic agent: depamide. Ann Med Psychol (paris) 124:707–710
Leniger T, Pageler L, Stude P, Diener HC, Limmroth V (2005) Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 45:42–46. https://doi.org/10.1111/j.1526-4610.2005.05009.x
Liampas I, Siokas V, Brotis A, Zintzaras E, Stefanidis I, Dardiotis E (2021) Intravenous sodium valproate in status epilepticus: review and Meta-analysis. Int J Neurosci 131:70–84. https://doi.org/10.1080/00207454.2020.1732967
Malamiri RA, Ghaempanah M, Khosroshahi N, Nikkhah A, Bavarian B, Ashrafi MR (2012) Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol 16:536–541. https://doi.org/10.1016/j.ejpn.2012.01.012
Mazaheri S, Poorolajal J, Hosseinzadeh A, Fazlian MM (2015) Effect of intravenous sodium valproate vs dexamethasone on acute migraine headache: a double blind randomized clinical trial. PLoS ONE 10. https://doi.org/10.1371/journal.pone.0120229
Misra UK, Dubey D, Kalita J (2017) Comparison of lacosamide versus sodium valproate in status epilepticus: a pilot study. Epilepsy Behav 76:110–113. https://doi.org/10.1016/j.yebeh.2017.07.005
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 3:e123-130
Nene D et al (2019) Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): a prospective randomized controlled pilot study. Seizure-European J Epilepsy 65:111–117. https://doi.org/10.1016/j.seizure.2019.01.015
New A, Tucci VT, Rios J (2017) A modern-day fight club? The stabilization and management of acutely agitated patients in the emergency department. Psychiatr Clin North Am 40:397–410. https://doi.org/10.1016/j.psc.2017.05.002
Norton JW, Quarles E (2000) Intravenous valproate in neuropsychiatry. Pharmacotherapy 20:88–92. https://doi.org/10.1592/phco.20.1.88.34657
Quinn NJ, Hohlfelder B, Wanek MR, Duggal A, Torbic H (2021) Prescribing practices of valproic acid for agitation and delirium in the intensive care unit. Ann Pharmacother 55:311–317. https://doi.org/10.1177/1060028020947173
Rahimdel A, Mellat A, Zeinali A, Jafari E, Ayatollahi P (2014) Comparison between intravenous sodium valproate and subcutaneous sumatriptan for treatment of acute migraine attacks; double-blind randomized clinical trial. Iran J Med Sci 39:171–177
Rajasekar S, Selvakumar P, Nazar RM (2019) Sodium valproate versus fosphenytoin for status epilepticus in children - a randomized control trial. J Evol Med Dent Sci-Jemds 8:1474–1478. https://doi.org/10.14260/jemds/2019/328
Regenold WT, Prasad M (2001) Uses of intravenous valproate in geriatric psychiatry. Am J Geriatr Psychiatry 9:306–308
Sekhar S, Kalra B, Mendhekar DN, Tekur U (2010) Efficacy of sodium valproate and haloperidol in the management of acute mania: a randomized open-label comparative study. J Clin Pharmacol 50:688–692. https://doi.org/10.1177/0091270009347870
Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, Bowden CL (2010) Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord 122:1–9. https://doi.org/10.1016/j.jad.2009.10.033
Su Y et al (2016) Phenobarbital versus valproate for generalized convulsive status epilepticus in adults: a prospective randomized controlled trial in China. CNS Drugs 30:1201–1207. https://doi.org/10.1007/s40263-016-0388-6
Tanen DA, Miller S, French T, Riffenburgh RH (2003) Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med 41:847. https://doi.org/10.1067/mem.2003.195
Venkataraman V, Wheless JW (1999) Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 35:147–153. https://doi.org/10.1016/s0920-1211(99)00005-4
Vignesh V, Rameshkumar R, Mahadevan S (2020) Comparison of phenytoin, valproate and levetiracetam in pediatric convulsive status epilepticus: a randomized double-blind controlled clinical trial. Indian Pediatr 57:222–227. https://doi.org/10.1007/s13312-020-1755-4
Wang F, Zhang H, Wang L, Cao Y, He Q (2020) Intravenous sodium valproate for acute migraine in the emergency department: a meta-analysis. Acta Neurol Scand 142:521–530. https://doi.org/10.1111/ane.13325
Wangemann M, Wolf C, Retzow A (1997) Replacement of oral valproate with intravenous valproate: a study on dose finding and bioavailability. Eur J Clin Res:209–215
Wheless JW, Vazquez BR, Kanner AM, Ramsay RE, Morton L, Pellock JM (2004) Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology 63:1507–1508. https://doi.org/10.1212/01.wnl.0000142077.14142.aa
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original version of this article was revised: This article was originally published with the name of the corresponding author was incorrectly presented. The first name should be Miriam and the surname should be Olivola.
Rights and permissions
About this article
Cite this article
Olivola, M., Civardi, S., Damiani, S. et al. Effectiveness and safety of intravenous valproate in agitation: a systematic review. Psychopharmacology 239, 339–350 (2022). https://doi.org/10.1007/s00213-021-06009-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-021-06009-0